Main navigation:



HCP’s Eye Care Model

Dr. Sanduk Ruit trains others on his cataract surgery techniques.

Creating Long-term, World Class Eye Care for the Poor

At the core of HCP’s success is its long-standing, trusted partnership with the Tilganga Eye Centre based in Kathmandu, Nepal. Together, HCP and Tilganga have dramatically improved eye care by creating a proven eye care model worthy of worldwide replication.

Reaching the greatest number of unserved blind people, with the highest quality care at the lowest cost possible, is HCP’s top priority. To do this as effectively as possible, HCP focuses in four key areas to ensure outstanding service:

  • Education, training and skill transfer to local medical professionals at all levels with proven medical techniques to improve surgery and surgical outcomes.
  • Outreach through mobile medical camps that reach the unserved in remote areas.
  • Cost effectiveness, high quality surgeries and medical procedures comparable to western standards.
  • Infrastructure building community eye centers to full specialty eye hospitals that ensure long-term, world class eye care.

Research Comparison of the HCP Model vs. the Western World Option

From "Fighting Global Blindness"

A trial was conducted in 2005 that compared the one of the world’s foremost phacoemulsification surgeons, Dr. David Chang at the University of California – San Francisco, who used the highest levels of technology available in the Western world, versus Dr. Ruit’s method of small incision sutureless cataract surgery, requiring an operating microscope as the only high technology instrument used in remote cataract outreach programs for the poorest people in Nepal.

The results from this trial were considered “dramatic.” The initial investment for Dr. Chang’s method was more than $100,000 USD for instruments and equipment in contrast to less than $15,000 for all the equipment needed to perform Dr. Ruit’s technique. The results equalized in six weeks, when there were no statistical differences in the outcomes. In both groups, 98% of the patients returned to excellent vision.